acyclovir and Nerve-Degeneration

acyclovir has been researched along with Nerve-Degeneration* in 2 studies

Trials

1 trial(s) available for acyclovir and Nerve-Degeneration

Article	Year
Idiopathic facial paralysis: a randomized, prospective, and controlled study using single-dose prednisone versus acyclovir three times daily. The Laryngoscope, 1998, Volume: 108, Issue:4 Pt 1 In a prospective, controlled, and randomized study, we compared the outcome of 101 Bell's palsy patients treated with acyclovir (54 patients) or prednisone (47 patients). The acyclovir dosage was 2400 mg (800 mg three times a day) for 10 days, and prednisone was given as a single daily dose of 1 mg/kg of body weight for 10 days and tapered to 0 over the next 6 days. Minimum follow-up was 3 months in all patients. Patients in the prednisone group had better clinical recovery than those treated with acyclovir. Less degree of neural degeneration was observed in the prednisone group compared with acyclovir patients. The incidence of sequelae was the same in both groups. According to these results, in a 10-day treatment cycle acyclovir given 800 mg three times is not as useful as prednisone given 1 mg/kg of body weight once a day in patients with idiopathic facial nerve paralysis. Topics: Acyclovir; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents; Antiviral Agents; Body Weight; Drug Administration Schedule; Facial Nerve; Facial Paralysis; Female; Follow-Up Studies; Glucocorticoids; Humans; Incidence; Male; Middle Aged; Nerve Degeneration; Prednisone; Prospective Studies; Treatment Outcome	1998

Article

Year

Idiopathic facial paralysis: a randomized, prospective, and controlled study using single-dose prednisone versus acyclovir three times daily.

The Laryngoscope, 1998, Volume: 108, Issue:4 Pt 1

In a prospective, controlled, and randomized study, we compared the outcome of 101 Bell's palsy patients treated with acyclovir (54 patients) or prednisone (47 patients). The acyclovir dosage was 2400 mg (800 mg three times a day) for 10 days, and prednisone was given as a single daily dose of 1 mg/kg of body weight for 10 days and tapered to 0 over the next 6 days. Minimum follow-up was 3 months in all patients. Patients in the prednisone group had better clinical recovery than those treated with acyclovir. Less degree of neural degeneration was observed in the prednisone group compared with acyclovir patients. The incidence of sequelae was the same in both groups. According to these results, in a 10-day treatment cycle acyclovir given 800 mg three times is not as useful as prednisone given 1 mg/kg of body weight once a day in patients with idiopathic facial nerve paralysis.

Topics: Acyclovir; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents; Antiviral Agents; Body Weight; Drug Administration Schedule; Facial Nerve; Facial Paralysis; Female; Follow-Up Studies; Glucocorticoids; Humans; Incidence; Male; Middle Aged; Nerve Degeneration; Prednisone; Prospective Studies; Treatment Outcome

1998

Other Studies

1 other study(ies) available for acyclovir and Nerve-Degeneration

Article	Year
Progression of MRI abnormalities in herpes simplex encephalitis despite clinical improvement: natural history or disease progression? Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2004, Volume: 25, Issue:2 Herpes simplex virus encephalitis (HSVE) is associated with a high mortality rate and a high probability of neurological sequelae. Good results are obtained when HSVE is promptly diagnosed and treated with acyclovir. We present a 71-year-old woman with clinically diagnosed HSVE, confirmed by PCR detection of HSV-1 DNA in the cerebrospinal fluid. She was treated with acyclovir (30 mg/kg day) for two weeks. Clinical and neuropsychological assessments 6 months after admission were normal; however MRI at 2, 6 and 12 months showed progressive deterioration with extensive white matter and cortical damage. Imaging studies of a cohort of patients surviving PCR-confirmed HSVE are needed to determine whether this pattern is occasional or a frequent form of progression. Topics: Acyclovir; Aged; Antiviral Agents; Cerebral Cortex; Cognition; Disease Progression; DNA, Viral; Encephalitis, Herpes Simplex; Female; Herpesvirus 1, Human; Humans; Magnetic Resonance Imaging; Nerve Degeneration; Neuropsychological Tests	2004

Article

Year

Progression of MRI abnormalities in herpes simplex encephalitis despite clinical improvement: natural history or disease progression?

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2004, Volume: 25, Issue:2

Herpes simplex virus encephalitis (HSVE) is associated with a high mortality rate and a high probability of neurological sequelae. Good results are obtained when HSVE is promptly diagnosed and treated with acyclovir. We present a 71-year-old woman with clinically diagnosed HSVE, confirmed by PCR detection of HSV-1 DNA in the cerebrospinal fluid. She was treated with acyclovir (30 mg/kg day) for two weeks. Clinical and neuropsychological assessments 6 months after admission were normal; however MRI at 2, 6 and 12 months showed progressive deterioration with extensive white matter and cortical damage. Imaging studies of a cohort of patients surviving PCR-confirmed HSVE are needed to determine whether this pattern is occasional or a frequent form of progression.

Topics: Acyclovir; Aged; Antiviral Agents; Cerebral Cortex; Cognition; Disease Progression; DNA, Viral; Encephalitis, Herpes Simplex; Female; Herpesvirus 1, Human; Humans; Magnetic Resonance Imaging; Nerve Degeneration; Neuropsychological Tests

2004